iBio's Q1 Loss Widens to $5.7M, Cash Reserves Jump Post-$50M Offering

Ticker: IBIO · Form: 10-Q/A · Filed: 2025-11-17T00:00:00.000Z

Sentiment: mixed

Topics: Biotechnology, AI Drug Discovery, Obesity Therapeutics, Preclinical Development, Cash Burn, Public Offering, SEC Filing

Related Tickers: IBIO

TL;DR

**iBio's cash infusion from a $50M offering buys it time to burn through R&D for its AI-driven obesity drug, but profitability remains a distant dream.**

AI Summary

iBio, Inc. (IBIO) reported a net loss of $5.72 million for the three months ended September 30, 2025, an increase from a net loss of $3.99 million in the same period of 2024. Revenue for the quarter was $100,000, up from zero in the prior year, indicating nascent commercial activity. Operating expenses significantly increased to $6.05 million from $4.11 million, primarily driven by a rise in research and development costs to $3.55 million from $1.31 million as the company advances its AI-driven drug discovery platform. Despite the losses, iBio's cash and cash equivalents surged to $28.11 million as of September 30, 2025, from $8.58 million on June 30, 2025, largely due to a $50 million gross proceeds public offering in August 2025. Total current assets dramatically increased to $50.77 million from $9.72 million, including $21.46 million in investments in debt securities. The company is strategically focused on developing next-generation antibody therapeutics for cardiometabolic and obesity diseases, with its lead candidate, IBIO-610, anticipated to commence human clinical trials in early 2027. The 10-Q/A filing specifically amends Exhibit 32.1 to include inadvertently omitted certification language, not altering financial figures.

Why It Matters

This filing is crucial for investors as it confirms iBio's strengthened liquidity position with $49.6 million in cash and debt securities, providing a runway for at least 12 months, alleviating immediate going concern doubts. The substantial increase in R&D spending to $3.55 million signals aggressive investment in its AI Drug Discovery Platform and preclinical pipeline, particularly IBIO-610 for obesity, a highly competitive and lucrative market. For employees, this financial stability ensures continued operations and investment in their San Diego R&D lab. Customers and the broader market will watch for progress on IBIO-610, as successful development could challenge existing GLP-1 therapies by targeting muscle preservation and selective fat loss, potentially disrupting the cardiometabolic space.

Risk Assessment

Risk Level: medium — The company reported a net loss of $5.72 million and negative cash flows from operations of $5.67 million for the three months ended September 30, 2025, indicating continued unprofitability. While the recent $50 million public offering significantly boosted cash and investments to $49.6 million, providing a 12-month runway, iBio remains a preclinical stage biotechnology company with no products on the market and anticipates its first human clinical trials for IBIO-610 only in early 2027, carrying inherent high development and commercialization risks.

Analyst Insight

Investors should monitor iBio's R&D progress closely, particularly milestones for IBIO-610 and any new strategic collaborations. Given the preclinical stage and continued losses, this is a speculative investment; consider a small position if bullish on their AI platform and obesity pipeline, but be prepared for significant volatility and long development timelines.

Financial Highlights

debt To Equity
0.14
revenue
$100K
operating Margin
-5951%
total Assets
$64.16M
total Debt
$8.12M
net Income
-$5.72M
eps
N/A
gross Margin
N/A
cash Position
$28.11M
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Product Sales$100KN/A

Key Numbers

Key Players & Entities

FAQ

What was iBio's net loss for the quarter ended September 30, 2025?

iBio, Inc. reported a net loss of $5.72 million for the three months ended September 30, 2025, which is an increase from the $3.99 million net loss reported for the same period in 2024.

How much cash and cash equivalents did iBio have as of September 30, 2025?

As of September 30, 2025, iBio, Inc. had $28.11 million in cash and cash equivalents, a substantial increase from $8.58 million as of June 30, 2025.

What was the primary reason for the increase in iBio's cash position?

The primary reason for the increase in iBio's cash position was the closing of an underwritten public offering in August 2025, which raised gross proceeds of approximately $50 million.

What is iBio's strategic focus for drug development?

iBio's strategic focus is on leveraging Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space, aiming for next-generation therapies that preserve muscle mass and target fat selectively.

When does iBio anticipate commencing human clinical trials for its lead candidate IBIO-610?

iBio anticipates the commencement of its first human clinical trials for its lead candidate, IBIO-610, in early 2027.

Did iBio generate any revenue in the quarter ended September 30, 2025?

Yes, iBio, Inc. generated $100,000 in revenue for the three months ended September 30, 2025, compared to no revenue in the same period of 2024.

What was the change in iBio's research and development expenses?

iBio's research and development expenses increased significantly to $3.55 million for the three months ended September 30, 2025, from $1.31 million in the same period of 2024.

What was the purpose of the 10-Q/A amendment filed by iBio?

The 10-Q/A amendment was filed by iBio, Inc. to include inadvertently omitted certification language in paragraphs 1 and 2 of Exhibit 32.1 (the PEO Section 906 Certification) from the original 10-Q filing.

Does iBio believe it has sufficient liquidity to fund operations for the next 12 months?

Yes, based on total cash and cash equivalents, and investments in debt securities of approximately $49.6 million at September 30, 2025, iBio believes its current cash position is sufficient to fund operations for at least 12 months.

What are the key principles of iBio's obesity strategy?

iBio's obesity strategy is built on three key principles: developing next-generation antibody therapeutics to address limitations of current treatments, focusing on targets with strong human validation to reduce development risk, and applying its integrated AI Drug Discovery Platform to rapidly generate development-ready biologics.

Risk Factors

Industry Context

The biopharmaceutical industry, particularly in areas like cardiometabolic and obesity diseases, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies often rely on novel platforms, such as AI-driven drug discovery, to gain a competitive edge and accelerate the identification of promising therapeutic candidates.

Regulatory Implications

iBio's focus on developing novel therapeutics means it is subject to stringent regulatory oversight by bodies like the FDA. The success of its lead candidate, IBIO-610, hinges on navigating complex clinical trial phases and obtaining regulatory approval, a process that is inherently uncertain and time-consuming.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]

Key Dates

Glossary

Comprehensive Loss
The total change in a company's equity during a period from non-owner sources, including net loss and other gains or losses not recognized in the income statement. (Indicates the overall financial performance beyond just the net income, reflecting all changes in equity from non-owner transactions.)
Additional Paid-in Capital
The amount of money a company receives from selling stock above its par value. (Represents capital raised from equity issuance, a key component of the company's equity structure.)
Accumulated Deficit
The total net losses a company has incurred since its inception, less any net income. (Shows the cumulative profitability of the company; a large deficit indicates a history of losses.)
Right-of-use Asset
An asset representing a lessee's right to use an underlying asset for the lease term under a lease agreement. (Reflects the company's use of leased assets, such as office or lab space, impacting operating expenses and balance sheet.)
Investments in Debt Securities
Financial instruments representing loans made by the investor to a borrower, typically with a fixed interest rate and maturity date. (A new asset class for iBio, contributing to its current assets and potentially generating interest income, but also carrying market risk.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, iBio has seen a significant increase in its net loss, rising to $5.72 million from $3.99 million, driven by a substantial jump in R&D expenses from $1.31 million to $3.55 million. While revenue has emerged at $100,000 from zero, it is insufficient to offset the increased operating costs. The company's financial position has been dramatically strengthened by a recent public offering, boosting cash and cash equivalents to $28.11 million and total current assets to $50.77 million, a stark contrast to the previous period's lower figures.

Filing Stats: 4,540 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2025-11-17 07:40:45

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 4 Item 1.

Financial Statements

Financial Statements: Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and June 30, 2025 4 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended September 30, 2025 and 2024 5 Unaudited Condensed Consolidated Statements of Stockholders' Equity for the three months ended September 30, 2025 and 2024 6 Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2025 and 2024 7 Notes to the Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3 .

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 4.

Controls and Procedures

Controls and Procedures 45

OTHER INFORMATION

PART II. OTHER INFORMATION 46 Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 50 Item 3. Defaults Upon Senior Securities 50 Item 4. Mine Safety Disclosures 50 Item 5. Other Information 50 Item 6. Exhibits 51

SIGNATURES

SIGNATURES 52 2 Table of Contents EXPLANATORY NOTE This Amendment No. 1 on Form 10-Q/A (the "Amendment") amends the Quarterly Report on Form 10-Q of iBio, Inc. (the "Company") for the quarter ended September 30, 2025, as filed with the U.S. Securities and Exchange Commission (the "SEC") on November 12, 2025 (the "Original 10-Q"). The purpose of this Amendment is to file a revised version of Exhibit 32.1 filed with the Original 10-Q. The Company is filing revised Exhibit 32.1, (the "PEO Section 906 Certification") in order to include certification language in paragraphs 1 and 2 that was inadvertently omitted from the PEO Section 906 Certification when originally filed. Except as expressly noted herein, this Amendment does not amend, update or change any other items or disclosures contained in the Original 10-Q, and accordingly, this Amendment does not reflect or purport to reflect any information or events occurring after the original filing date of the Original 10-Q or modify or update those disclosures affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original 10-Q. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), new certifications by the Company's principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. 3 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited). iBio, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) September 30, June 30, 2025 2025 (Unaudited) Assets Current assets: Cash and cash equivalents $ 28,111 $ 8,582 Accounts receivable - trade 65 — Investments in debt securities (adjusted cost $ 21,471 and $ 0 , respectively - see Note 6) 21,456 — Subscription receivable — 105 Prepaid expenses and other current assets 1,140 1,034 Total Current Assets 50,772 9,721 Restricted cash 228 210 Promissory note receivable 1,118 1,098 Finance lease right-of-use assets, net of accumulated amortization — 68 Operating lease right-of-use asset 1,958 2,051 Fixed assets, net of accumulated depreciation 3,210 3,163 Intangible assets, net of accumulated amortization 6,843 6,848 Security deposits 26 26 Total Assets $ 64,155 $ 23,185 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,822 $ 2,188 Accrued expenses 850 1,345 Finance lease obligations — 53 Operating lease obligation - current portion 504 490 Equipment financing payable - current portion 16 64 Term promissory note 706 766 Contract liabilities 1,150 1,200 Total Current Liabilities 6,048 6,106 Operating lease obligation - net of current portion 2,068 2,199 Total Liabilities 8,116 8,305 Stockholders' Equity Series 2022 Convertible Preferred Stock - $ 0.001 par value; 1,000,000 shares authorized at September 30, 2025 and June 30, 2025; 0 shares issued and outstanding as of September 30, 2025 and June 30, 2025 — — Common Stock - $ 0.001 par value; 275,000,000 shares authorized at September 30, 2025 and June 30, 2025; 20,254,599 and 19,349,201 shares issued and outstanding as of September 30, 2025 and June 30, 2025, respectively 20 19 Additional paid-in capital 393,978 347,085

View on Read The Filing